Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M, Tamiya A, Suzuki H, Taniguchi Y, Katayama K, Minomo S, Nakao K, Takeuchi N, Matsuda Y, Naito Y, Shiroyama T, Okamoto N, Okishio K, Kumagai T, Atagi S, Imamura F, Hirashima T.
Tamiya M, et al. Among authors: nakao k.
Invest New Drugs. 2021 Aug;39(4):1106-1112. doi: 10.1007/s10637-021-01076-8. Epub 2021 Feb 5.
Invest New Drugs. 2021.
PMID: 33544282
Clinical Trial.